MA50438B1 - Promédicaments de dérivés de triazole substitués, et utilisations de ceux-ci - Google Patents
Promédicaments de dérivés de triazole substitués, et utilisations de ceux-ciInfo
- Publication number
- MA50438B1 MA50438B1 MA50438A MA50438A MA50438B1 MA 50438 B1 MA50438 B1 MA 50438B1 MA 50438 A MA50438 A MA 50438A MA 50438 A MA50438 A MA 50438A MA 50438 B1 MA50438 B1 MA 50438B1
- Authority
- MA
- Morocco
- Prior art keywords
- prodrugs
- triazol
- carboxamide
- trifluoro
- chlorophenyl
- Prior art date
Links
- 239000000651 prodrug Substances 0.000 title abstract 2
- 229940002612 prodrug Drugs 0.000 title abstract 2
- 229940042055 systemic antimycotics triazole derivative Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- OSVUKJSOVIXPMR-ZDUSSCGKSA-N 5-[[3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-1,2,4-triazol-1-yl]methyl]-2-(3-chloropyridin-2-yl)-1,2,4-triazole-3-carboxamide Chemical compound ClC1=CC=C(C=C1)C1=NN(C(N1C[C@@H](C(F)(F)F)O)=O)CC1=NN(C(=N1)C(=O)N)C1=NC=CC=C1Cl OSVUKJSOVIXPMR-ZDUSSCGKSA-N 0.000 abstract 1
- YPJGHBRCKDZNEG-HNNXBMFYSA-N 5-[[3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-1,2,4-triazol-1-yl]methyl]-2-[2-(trifluoromethyl)phenyl]-1,2,4-triazole-3-carboxamide Chemical compound NC(=O)C1=NC(CN2N=C(N(C[C@H](O)C(F)(F)F)C2=O)C2=CC=C(Cl)C=C2)=NN1C1=C(C=CC=C1)C(F)(F)F YPJGHBRCKDZNEG-HNNXBMFYSA-N 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000027032 Renal vascular disease Diseases 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000015670 renal artery disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne des promédicaments de 3-({3-(4-chlorophényl)-5-oxo-4-[(2s)-3,3,3-trifluoro- 2-hydroxypropyl] -4,5-dihydro- 1h-1,2,4-triazol-1-yl jméthyl)-1- [3-(trifluorométhyl)-pyridin-2-yl] - 1h-1,2,4-triazole-5-carboxamide, 3-({3-(4-chlorophényl)-5-oxo-4-[(2s)-3,3,3-trifluoro-2- hydroxypropyl] -4,5-dihydro- 1h-1,2,4-triazol-1-yl} méthyl)-1- [2-(trifluorométhyl)-phényl] -1h- 1,2,4-triazole-5-carboxamide et 3-({3-(4-chlorophényl)-5-oxo-4-[(2s)-3,3,3-trifluoro-2- hydroxypropyl] -4,5-dihydro-1h-1,2,4-triazol-1-yl} méthyl)-1-(3-chloropyridin-2-yl)-1h-1,2,4- triazole-5-carboxamide, des procédés pour la préparation de tels composés, des compositions pharmaceutiques contenant de tels composés, et l'utilisation de tels composés ou compositions pour le traitement et/ou la prévention de maladies, en particulier pour le traitement et/ou la prévention de maladies rénales et cardiovasculaires.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17197935 | 2017-10-24 | ||
| PCT/EP2018/078364 WO2019081292A1 (fr) | 2017-10-24 | 2018-10-17 | Promédicaments de dérivés de triazole substitués, et utilisations de ceux-ci |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA50438A MA50438A (fr) | 2020-09-02 |
| MA50438B1 true MA50438B1 (fr) | 2022-03-31 |
Family
ID=60162099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA50438A MA50438B1 (fr) | 2017-10-24 | 2018-10-17 | Promédicaments de dérivés de triazole substitués, et utilisations de ceux-ci |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US11298367B2 (fr) |
| EP (1) | EP3700913B1 (fr) |
| JP (1) | JP2021500365A (fr) |
| KR (1) | KR20200069361A (fr) |
| CN (1) | CN111225921A (fr) |
| AR (1) | AR113791A1 (fr) |
| AU (1) | AU2018356352A1 (fr) |
| BR (1) | BR112020007983A2 (fr) |
| CA (1) | CA3079767A1 (fr) |
| CL (1) | CL2020001076A1 (fr) |
| CO (1) | CO2020004945A2 (fr) |
| CR (1) | CR20200176A (fr) |
| CU (1) | CU24604B1 (fr) |
| CY (1) | CY1124938T1 (fr) |
| DK (1) | DK3700913T3 (fr) |
| DO (1) | DOP2020000076A (fr) |
| EA (1) | EA202091025A1 (fr) |
| EC (1) | ECSP20023056A (fr) |
| ES (1) | ES2906305T3 (fr) |
| HR (1) | HRP20220060T1 (fr) |
| HU (1) | HUE057278T2 (fr) |
| IL (1) | IL273949A (fr) |
| JO (1) | JOP20200099A1 (fr) |
| LT (1) | LT3700913T (fr) |
| MA (1) | MA50438B1 (fr) |
| MX (1) | MX2020004191A (fr) |
| NI (1) | NI202000030A (fr) |
| PE (1) | PE20210394A1 (fr) |
| PH (1) | PH12020550473A1 (fr) |
| PL (1) | PL3700913T3 (fr) |
| PT (1) | PT3700913T (fr) |
| RS (1) | RS62984B1 (fr) |
| SG (1) | SG11202003049WA (fr) |
| SI (1) | SI3700913T1 (fr) |
| TW (1) | TW201932117A (fr) |
| UA (1) | UA126456C2 (fr) |
| UY (1) | UY37948A (fr) |
| WO (1) | WO2019081292A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021259852A1 (fr) | 2020-06-25 | 2021-12-30 | Bayer Aktiengesellschaft | Procédé de préparation de dérivés de 5-(alcoxycarbonyle)-et de 5- (carboxamide)-1-aryl-1,2,4-triazole |
| WO2022112213A1 (fr) | 2020-11-30 | 2022-06-02 | Bayer Aktiengesellschaft | Formes cristallines de 3-[[3-(4-chlorophényl)-5-oxo-4-((2s)-3,3,3-trifluoro-2-hydroxypropyl)-4,5-dihydro-1h-1,2,4-triazol-1-yl]méthyl]-1-[3- (trifluorométhyl)pyridin-2-yl]-1h-1,2,4-triazole-5-carboxamide |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3966781A (en) | 1970-12-17 | 1976-06-29 | Merck Sharp & Dohme (I.A.) Corporation | Deuteration of functional group-containing hydrocarbons |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
| AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
| DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| EP1701959A1 (fr) | 2003-12-22 | 2006-09-20 | Pfizer Limited | Dérivés de triazole comme antagonistes de vasopréssine |
| MXPA06012510A (es) | 2004-04-28 | 2006-12-15 | Pfizer | Derivados de 3-heterociclil-4-fenil-triazol como inhibidores del receptor de vasopresina via. |
| CL2008003301A1 (es) * | 2007-11-06 | 2009-10-16 | Astrazeneca Ab | Compuestos derivados de 3,4-dihidropirazina-2-carboxamida, inhibidores de la elastasa de neutrofilos humanos; composiciones farmacéuticas; procesos de preparación de compuestos y composición farmacéutica; y uso en el tratamiento de síndrome de dificultad respiratoria de los adultos, fibrosis quística, cáncer, entre otras. |
| DE102010001064A1 (de) | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung |
| AR076542A1 (es) * | 2009-05-22 | 2011-06-22 | Merck Sharp & Dohme | Antagonistas del receptor de orexina de isonicotinamida |
| MA34019B1 (fr) | 2010-02-27 | 2013-02-01 | Bayer Ip Gmbh | Aryltriazolone liée à un bis-aryle et son utilisation |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| CN103097387B (zh) | 2010-07-09 | 2016-11-02 | 拜耳知识产权有限责任公司 | 环稠合的嘧啶和三嗪以及其用于治疗和/或预防心血管疾病的用途 |
| DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
| DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
| WO2012112363A1 (fr) | 2011-02-14 | 2012-08-23 | Merck Sharp & Dohme Corp. | Inhibiteurs de cystéine protéases, les cathepsines |
| AU2014336178B2 (en) * | 2013-10-16 | 2018-03-01 | Bayer Cropscience Aktiengesellschaft | Active compound combinations comprising a (thio)carboxamide derivative and a fungicidal compound |
| ES2697902T3 (es) | 2014-11-03 | 2019-01-29 | Bayer Pharma AG | Derivados de feniltriazol sustituido con hidroxialquilo y sus usos |
| UY36571A (es) * | 2015-03-05 | 2016-09-30 | Bayer Cropscience Ag | Combinaciones de compuestos activos |
| US10525041B2 (en) | 2016-05-03 | 2020-01-07 | Bayer Pharma Aktiengesellschaft | Fluoroalkyl-substituted aryltriazole derivatives and uses thereof |
| US9988367B2 (en) | 2016-05-03 | 2018-06-05 | Bayer Pharma Aktiengesellschaft | Amide-substituted pyridinyltriazole derivatives and uses thereof |
| US10815205B2 (en) | 2016-05-03 | 2020-10-27 | Bayer Pharma Aktiengesellschaft | Amide-substituted phenyltriazole derivatives and uses thereof |
| WO2017191114A1 (fr) | 2016-05-03 | 2017-11-09 | Bayer Aktiengesellschaft | Dérivés d'hétéroaryltriazole substitués par hydroxyalkyle et utilisations associées |
| US10800746B2 (en) | 2016-05-03 | 2020-10-13 | Bayer Pharma Aktiengesellschaft | Oxoalkyl-substituted phenyltriazole derivatives and uses thereof |
| US20190119251A1 (en) | 2016-05-03 | 2019-04-25 | Bayer Pharma Aktiengesellschaft | Amide-substituted aryltriazole derivatives and uses thereof |
| EP3529244A1 (fr) | 2016-10-20 | 2019-08-28 | Bayer Pharma Aktiengesellschaft | Dérivés de triazole substitués par hydroxyalkyle et utilisations associées |
-
2018
- 2018-10-17 CR CR20200176A patent/CR20200176A/es unknown
- 2018-10-17 WO PCT/EP2018/078364 patent/WO2019081292A1/fr unknown
- 2018-10-17 DK DK18785394.0T patent/DK3700913T3/da active
- 2018-10-17 UA UAA202003139A patent/UA126456C2/uk unknown
- 2018-10-17 CN CN201880068846.5A patent/CN111225921A/zh active Pending
- 2018-10-17 ES ES18785394T patent/ES2906305T3/es active Active
- 2018-10-17 BR BR112020007983-9A patent/BR112020007983A2/pt not_active Application Discontinuation
- 2018-10-17 LT LTEPPCT/EP2018/078364T patent/LT3700913T/lt unknown
- 2018-10-17 CU CU2020000040A patent/CU24604B1/es unknown
- 2018-10-17 EA EA202091025A patent/EA202091025A1/ru unknown
- 2018-10-17 SG SG11202003049WA patent/SG11202003049WA/en unknown
- 2018-10-17 HR HRP20220060TT patent/HRP20220060T1/hr unknown
- 2018-10-17 SI SI201830540T patent/SI3700913T1/sl unknown
- 2018-10-17 PE PE2020000813A patent/PE20210394A1/es unknown
- 2018-10-17 EP EP18785394.0A patent/EP3700913B1/fr active Active
- 2018-10-17 CA CA3079767A patent/CA3079767A1/fr not_active Abandoned
- 2018-10-17 JP JP2020522855A patent/JP2021500365A/ja active Pending
- 2018-10-17 US US16/758,742 patent/US11298367B2/en active Active
- 2018-10-17 MX MX2020004191A patent/MX2020004191A/es unknown
- 2018-10-17 KR KR1020207014412A patent/KR20200069361A/ko not_active Application Discontinuation
- 2018-10-17 JO JOP/2020/0099A patent/JOP20200099A1/ar unknown
- 2018-10-17 HU HUE18785394A patent/HUE057278T2/hu unknown
- 2018-10-17 RS RS20220036A patent/RS62984B1/sr unknown
- 2018-10-17 PT PT187853940T patent/PT3700913T/pt unknown
- 2018-10-17 AU AU2018356352A patent/AU2018356352A1/en not_active Abandoned
- 2018-10-17 MA MA50438A patent/MA50438B1/fr unknown
- 2018-10-17 PL PL18785394T patent/PL3700913T3/pl unknown
- 2018-10-22 TW TW107137148A patent/TW201932117A/zh unknown
- 2018-10-24 UY UY0001037948A patent/UY37948A/es not_active Application Discontinuation
- 2018-10-24 AR ARP180103099A patent/AR113791A1/es unknown
-
2020
- 2020-04-13 IL IL273949A patent/IL273949A/en unknown
- 2020-04-21 EC ECSENADI202023056A patent/ECSP20023056A/es unknown
- 2020-04-22 CO CONC2020/0004945A patent/CO2020004945A2/es unknown
- 2020-04-22 PH PH12020550473A patent/PH12020550473A1/en unknown
- 2020-04-22 CL CL2020001076A patent/CL2020001076A1/es unknown
- 2020-04-23 NI NI202000030A patent/NI202000030A/es unknown
- 2020-05-06 DO DO2020000076A patent/DOP2020000076A/es unknown
-
2022
- 2022-02-01 CY CY20221100084T patent/CY1124938T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA40893B1 (fr) | Dérivés de phényltriazole à substitution hydroxyalkyle et utilisations associées | |
| MA44851B1 (fr) | Dérivés pyridinyltriazole substitués par des groupements amides et leurs utilisations | |
| MA50438B1 (fr) | Promédicaments de dérivés de triazole substitués, et utilisations de ceux-ci | |
| MA33419B1 (fr) | Composés et compositions pour le traitement de maladies parasitaires | |
| KR910021398A (ko) | 트리아졸 항진균제 | |
| TNSN04164A1 (fr) | Inhibiteurs de acc. | |
| MA30629B1 (fr) | Derives de pyrazole servant d'inhibiteurs du cytochrome p450 | |
| MA29791B1 (fr) | Composes therapeutiques. | |
| MA29377B1 (fr) | Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif | |
| MA30672B1 (fr) | Utilisation de derives de l'azabicyclo hexane | |
| MA34903B1 (fr) | Derives de type azaindazole ou diazaindazole utilises comme medicaments | |
| MA49673B1 (fr) | Combinaison comprenant du palbociclib et 6-(2,4-dichlorophényl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulène-2-acide carboxylique et sa utilisation pour le traitement du cancer | |
| MA30166B1 (fr) | Imidazoles substitues et leur utilisation comme pesticides. | |
| MA46101A (fr) | Modulateurs allostériques positifs du récepteur muscarinique m1 | |
| MA45598B1 (fr) | Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda | |
| MA29816B1 (fr) | Composes de benzimidazole thiophene | |
| MA38358A1 (fr) | Formulations de composés organiques | |
| MA46077A1 (fr) | Composés et mélanges fongicides pour la lutte contre les maladies fongiques dans des céréales | |
| MA38425A1 (fr) | Composés bicycliques pour une utilisation comme agonistes selectifs pour le recepteur s1p1 | |
| MA33166B1 (fr) | Utilisation de dérivés de pyrimidylaminobenzamide pour le traitement de la fibrose | |
| MA46137A1 (fr) | Composés fongicides et mélanges de régulation des champignons dans les céréales | |
| NO20084913L (no) | Sammensetning inneholdende en jernchelator og et anti-neoplatisk middel og anvendelse derav | |
| MA46135A1 (fr) | Composés et mélanges fongicides pour la lutte contre les maladies fongiques dans des céréales | |
| MA46076A1 (fr) | Composés fongicides et mélanges de régulation des champignons dans les céréales | |
| MX2019014836A (es) | Formulaciones estabilizadas que contienen protioconazol con bajo contenido de 2-(1-clorociclopropanil)-1-(2-clorofenil)-3-(1h-1,2,4 -triazol-1-il)propan-2-ol. |